HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA.

AbstractAIMS:
The post-discharge outcomes of patients with cancer who undergo PCI are not well understood. This study evaluates the rates of readmissions within 90 days for acute myocardial infarction (AMI) and bleeding among patients with cancer who undergo percutaneous coronary intervention (PCI).
METHODS AND RESULTS:
Patients treated with PCI in the years from 2010 to 2014 in the US Nationwide Readmission Database were evaluated for the influence of cancer on 90-day readmissions for AMI and bleeding. A total of 1 933 324 patients were included in the analysis (2.7% active cancer, 6.8% previous history of cancer). The 90-day readmission for AMI after PCI was higher in patients with active cancer (12.1% in lung, 10.8% in colon, 7.5% in breast, 7.0% in prostate, and 9.1% for all cancers) compared to 5.6% among patients with no cancer. The 90-day readmission for bleeding after PCI was higher in patients with active cancer (4.2% in colon, 1.5% in lung, 1.4% in prostate, 0.6% in breast, and 1.6% in all cancer) compared to 0.6% among patients with no cancer. The average time to AMI readmission ranged from 26.7 days for lung cancer to 30.5 days in colon cancer, while the average time to bleeding readmission had a higher range from 38.2 days in colon cancer to 42.7 days in breast cancer.
CONCLUSIONS:
Following PCI, patients with cancer have increased risk for readmissions for AMI or bleeding, with the magnitude of risk depending on both cancer type and the presence of metastasis.
AuthorsChun Shing Kwok, Chun Wai Wong, Evangelos Kontopantelis, Ana Barac, Sherry-Ann Brown, Poonam Velagapudi, Anthony A Hilliard, Aditya S Bharadwaj, M Chadi Alraies, Mohamed Mohamed, Deepak L Bhatt, Mamas A Mamas
JournalEuropean heart journal (Eur Heart J) Vol. 42 Issue 10 Pg. 1019-1034 (03 07 2021) ISSN: 1522-9645 [Electronic] England
PMID33681960 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightPublished on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: [email protected].
Topics
  • Aftercare
  • Humans
  • Male
  • Myocardial Infarction (complications, epidemiology, therapy)
  • Neoplasms (complications, epidemiology, therapy)
  • Patient Discharge
  • Patient Readmission
  • Percutaneous Coronary Intervention
  • Treatment Outcome
  • United States (epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: